Junshi Biosciences' Toripalimab Plus Chemotherapy Cuts Death Risk 34% in Phase 3 Lung Cancer Trial

• Junshi Biosciences announced final Phase 3 NEOTORCH results on Oct. 27, 2026, for toripalimab with chemotherapy in resectable stage II-III lung cancer.
• The perioperative treatment significantly improved overall survival and delayed recurrence, progression or death versus chemotherapy alone in non-small cell lung cancer.
• Results were presented at the 2026 ESMO Congress and simultaneously published in Annals of Oncology.
• Safety remained manageable, with no new safety signals identified.
• China’s NMPA accepted an application in July 2026 to expand toripalimab’s perioperative indication to resectable stage II-III disease, based on these results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610272348OMX_____CNEWS_EN_GNW9854887_en) on October 28, 2026, and is solely responsible for the information contained therein.